The cGAS-STING pathway is an innate immune cytosolic DNA-sensing axis in which cGAS detects genomic instability or mitochondrial damage and activates STING to drive a type I interferon (IFN-I) response. It is implicated across neurodegeneration, cancer immunotherapy, inflammatory skin disease, and wound healing, with persistent activation linked to chronic neuroinflammation and dopaminergic neuronal loss in parkinsons disease. In Parkinson’s disease, sustained signaling in microglia is highlighted as a mechanistic and therapeutic target, while alpha-synuclein aggregation may converge to maintain pathway activation. In cancer, multiple studies used agonists or nanoplatforms such as diabzi, mn2+, and scys p mnco to amplify STING signaling, remodel the tumor microenvironment, and enhance T-cell responses. Recent work also shows mtDNA-driven activation in dermal fibroblasts in vitiligo and mtDNA-mediated inflammation that can be suppressed by eq nps, underscoring the pathway’s role in sterile inflammation. Overall, the literature emphasizes that cGAS-STING can be either pathogenic or therapeutically harnessed depending on context, especially when mitochondrial DNA release, intracellular DNA networks, or Mn2+-sensitized cGAS activation are involved.
Neurodegeneration
- cGAS-STING signaling is implicated in Parkinson’s disease pathogenesis through cytosolic DNA sensing and IFN-I activation, with persistent activation promoting chronic neuroinflammation and dopaminergic neuronal loss. (PMID:41500413)
- Emerging evidence indicates that alpha-synuclein aggregation may converge to sustain cGAS-STING pathway activation in Parkinson’s disease. (PMID:41500413)
- Persistent stimulation of the pathway in microglia is described as a driver of chronic neuroinflammation and a disease-modifying therapeutic target. (PMID:41500413)
Cancer / Immunotherapy
- mn2+ was reported to activate the pathway by sensitizing cGAS to cytosolic DNA, driving robust T cell-mediated antitumor immunity. (PMID:41949057)
- diabzi activates cGAS-STING signaling to amplify type I interferon responses and remodel the tumor microenvironment. (PMID:41973478)
- An in situ-formed DNA network hyperactivated STING signaling, with mir 155 and telomerase-driven strand elongation contributing to intracellular DNA network assembly. (PMID:41724120)
- scys p mnco drives cGAS-STING activation through X-ray-responsive Mn2+ release to enhance radio-immunotherapy. (PMID:42023514)
- Multi-ion channel nanomedicines that disrupt copper/iron homeostasis were reported to enhance tumor immunotherapy in part through this innate immune axis. (PMID:41944068)
Inflammation / Autoimmunity / Tissue Repair
- Released mtDNA activated the pathway in dermal fibroblasts and contributed to inflammatory signaling in vitiligo pathogenesis. (PMID:41722540)
- eq nps significantly inhibited activation of the mtDNA-mediated cGAS-STING pathway to relieve inflammation. (PMID:41512500)
- A mitochondria-targeted co-assembled nanosystem controlled mitochondrial DNA levels to alleviate inflammation and promote chronic wound healing. (PMID:41512500)
- mtDNA release and immunogenic cell death activate cGAS-STING and link to dendritic-cell maturation, supporting downstream immune activation. (PMID:41944068)
Mechanistic Advances / Delivery Platforms
- Intracellular DNA network assembly triggered by microRNA and telomerase was used for imaging-guided STING hyperactivation, with the network acting as a potent cGAS agonist and robust STING activator. (PMID:41724120)
- The pathway was activated downstream of mtDNA release and immunogenic cell death, illustrating how endogenous DNA damage signals can be converted into immune stimulation. (PMID:41944068)
- Radiotherapy-induced activation was further amplified by Mn2+ release in a nanoplatform, showing how ion delivery can potentiate cGAS-STING signaling. (PMID:42023514)
- VDAC1-dependent mtDNA release was identified as a trigger of fibroblast innate immune activation, providing a mechanistic handle for pathway inhibition. (PMID:41722540)